Urinary Metabolomic Signatures Linked to Left Ventricular Hypertrophy in Chronic Kidney Disease
Although left ventricular hypertrophy (LVH) is common in people with chronic kidney disease (CKD); its mechanisms are not well understood. Metabolomic profiling may reveal novel mechanistic pathways linked to cardiac rem
Left ventricular hypertrophy (LVH) represents a significant structural adaptation of the heart often observed in individuals with chronic kidney disease (CKD). Understanding the underlying mechanisms driving this cardiac remodeling is critical for metabolic and cardiovascular research, as it may inform potential therapeutic targets. Recent investigations into urinary metabolomic signatures aim to identify specific biochemical alterations associated with LVH development in CKD populations.
This study employed an exploratory approach using untargeted gas chromatography–mass spectrometry (GC–MS) to analyze urine samples from fifty-three adults diagnosed with CKD stages G2 through G4. Participants were stratified into two groups based on echocardiographic findings: those exhibiting LVH and those without. Statistical analyses included fold change analysis, t-tests with false discovery rate correction, principal component analysis, and orthogonal partial least squares–discriminant analysis to evaluate metabolic differences between the cohorts.
Key findings indicate that CKD patients with LVH exhibited lower urinary citrate levels alongside elevated concentrations of myristic acid and glycerol monoesters. Conversely, individuals without LVH demonstrated higher levels of 2-bromosebacic acid. Pathway enrichment analysis utilizing the Small Molecule Pathway Database implicated alterations in the tricarboxylic acid (TCA) cycle, pyruvate metabolism, gluconeogenesis, fatty acid oxidation, and amino acid metabolism. These results suggest that metabolic shifts involving mitochondrial energy production and lipid processing are associated with LVH.
The authors caution that these findings derive from a single-centre cross-sectional study design, which limits the ability to infer causality. While urinary metabolomic profiling offers promising insights into potential mechanistic pathways linking CKD to cardiac remodeling, larger multi-center studies are required to validate these associations. This research underscores the utility of metabolomics in identifying biomarkers for cardiovascular complications in renal disease but does not provide clinical recommendations or diagnostic guidelines.